Compounds > selegiline
Page last updated: 2024-08-23

selegiline and warfarin

selegiline has been researched along with warfarin in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.00)18.2507
2000's8 (40.00)29.6817
2010's10 (50.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Gozalbes, R; Pineda-Lucena, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Gross, G; Lehmann, H; Löscher, W; Teschendorf, HJ; Traut, M1
Bass, AE; Bruce, G; Bylov, IE; Fry, JR; Hammond, AH; Jassi, KL; Kovalenko, SM; Laughton, C; Shaw, PN1
Han, XH; Hong, SS; Hwang, BY; Hwang, JH; Hwang, JS; Jeong, SH; Lee, D; Lee, MK; Ro, JS1
Delogu, G; Matos, MJ; Orallo, F; Picciau, C; Quezada, E; Santana, L; Uriarte, E; Viña, D1
Matos, MJ; Santana, L; Uriarte, E; Vazquez-Rodriguez, S; Viña, D1
Borges, F; Cadoni, E; Ferino, G; Laguna, R; Matos, MJ; Santana, L; Uriarte, E; Viña, D1
Fontenla, JA; Friedman, C; Gonzalez-Franco, RM; Matos, MJ; Santana, L; Tatonetti, NP; Uriarte, E; Vilar, S; Viña, D1
Estrada, M; Hripcsak, G; Matos, MJ; Rodríguez-Enríquez, F; Rodríguez-Franco, MI; Santana, L; Uriarte, E; Vilar, S; Viña, D1
Alcaro, S; Bagetta, D; Borges, F; Fonseca, A; Matos, MJ; Ortuso, F; Reis, J; Silva, T; Uriarte, E1
Bhatia, M; Kapoor, A; Kumar, A; Kumar, P; Kumar, S1

Reviews

2 review(s) available for selegiline and warfarin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Monoamine oxidase inhibitors: A concise review with special emphasis on structure activity relationship studies.
    European journal of medicinal chemistry, 2022, Nov-15, Volume: 242

    Topics: Aldehydes; Ammonia; Caffeine; Chalcones; Chromones; Clorgyline; Coumarins; Hydrogen Peroxide; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Pyrazoles; Selegiline; Structure-Activity Relationship; Thiazoles; Thiourea

2022

Other Studies

18 other study(ies) available for selegiline and warfarin

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
QSAR-based solubility model for drug-like compounds.
    Bioorganic & medicinal chemistry, 2010, Oct-01, Volume: 18, Issue:19

    Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water

2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 288, Issue:3

    Topics: Animals; Anticonvulsants; Brain; Coumarins; Electric Stimulation; Epilepsy, Temporal Lobe; Female; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rats; Rats, Wistar; Selegiline; Tranylcypromine

1999
Selectivity of 7-alkoxycoumarins as probe substrates for rat hepatic cytochrome P450 forms is influenced by the substitution pattern on the coumarin nucleus.
    Xenobiotica; the fate of foreign compounds in biological systems, 2004, Volume: 34, Issue:8

    Topics: 7-Alkoxycoumarin O-Dealkylase; Adolescent; Adult; Aged; Animals; beta-Naphthoflavone; Coumarins; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B1; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Isoenzymes; Male; Microsomes, Liver; Middle Aged; Molecular Probes; Molecular Structure; Phenobarbital; Rats; Rats, Wistar; Selegiline; Substrate Specificity

2004
Monoamine oxidase inhibitory coumarins from the aerial parts of Dictamnus albus.
    Archives of pharmacal research, 2006, Volume: 29, Issue:12

    Topics: Animals; Brain; Clorgyline; Coumarins; Dictamnus; Dose-Response Relationship, Drug; In Vitro Techniques; Kinetics; Magnetic Resonance Spectroscopy; Mice; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Selegiline; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet

2006
A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.
    Bioorganic & medicinal chemistry letters, 2009, Jun-15, Volume: 19, Issue:12

    Topics: Antioxidants; Coumarins; Drug Design; Humans; Inhibitory Concentration 50; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Resveratrol; Selegiline; Stilbenes; Structure-Activity Relationship

2009
MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.
    Bioorganic & medicinal chemistry letters, 2011, Jul-15, Volume: 21, Issue:14

    Topics: Coumarins; Humans; Iproniazid; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Selegiline

2011
8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies.
    ChemMedChem, 2012, Mar-05, Volume: 7, Issue:3

    Topics: Alzheimer Disease; Coumarins; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Protein Binding; Protein Isoforms; Selegiline; Solutions

2012
Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
    European journal of medicinal chemistry, 2013, Volume: 63

    Topics: Animals; Biocatalysis; Carbamates; Coumarins; Dose-Response Relationship, Drug; Humans; Hydrogen Peroxide; Mice; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Protein Binding; Protein Structure, Tertiary; Selegiline; Substrate Specificity; Tyramine

2013
Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives.
    Bioorganic & medicinal chemistry letters, 2015, Feb-01, Volume: 25, Issue:3

    Topics: Binding Sites; Coumarins; Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Isoforms; Protein Structure, Tertiary; Selegiline; Structure-Activity Relationship

2015
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
    Journal of medicinal chemistry, 2017, 08-24, Volume: 60, Issue:16

    Topics: Alanine; Benzylamines; Chromones; Clorgyline; Coumarins; Humans; Indans; Kinetics; Ligands; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Selegiline; Structure-Activity Relationship

2017